StockNews.com Initiates Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research note issued on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Trading Down 1.2 %

Shares of NASDAQ TTNP opened at $4.14 on Tuesday. The stock has a fifty day moving average price of $3.64 and a 200 day moving average price of $4.04. Titan Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $14.80. The company has a market cap of $3.78 million, a P/E ratio of -0.79 and a beta of 1.19.

Titan Pharmaceuticals (NASDAQ:TTNP) last posted its earnings results on Thursday, March 20th. The specialty pharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.